Mateos, M., Puig, N. (2025). Accelerating Myeloma Drug Development: Will Minimal Residual Disease Replace Progression-Free Survival as an Intermediate Surrogate End Point?. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00048